Safety and Efficacy of Epicardial Implantation of Collagen Membranes With Allogeneic Adipose Derived Stem Cells
← catalyst calendarNCT06956807 · readout in 134 d
Sponsored by Viscofan (industry) · VIS.MC — their whole pipeline →. With KCRI Sp. z o.o., Medical University of Silesia, Clinica Universidad de Navarra, Universidad de Navarra, Hospital General Universitario Gregorio Marañon.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
10estimated
Sites
1
Country
Poland
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-01 | estimated | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- CABG-patients
- Heart Failure
- Myocardial Infarction (MI)
Intervention
- Combination product: VB-C01 cellularised patch
Primary outcome
what the primary-completion date above is the date OFcombination of MACCEs at all follow up visits during the first year after treatment
measured 12 months
Permalink · VIS.MC's whole pipeline · Catalyst calendar · Every registered study · What changed